Seaport Therapeutics, Inc. Common Stock (SPTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Seaport Therapeutics, Inc. Common Stock (SPTX) has a cash flow conversion efficiency ratio of -0.062x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.14 Million) by net assets ($422.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Seaport Therapeutics, Inc. Common Stock worth for the company's overall valuation and market capitalisation.
Seaport Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Seaport Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Seaport Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seaport Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See Seaport Therapeutics, Inc. Common Stock (SPTX) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488
|
0.025x |
|
Capital Clean Energy Carriers Corp.
NASDAQ:CCEC
|
0.040x |
|
Berkshire Hills Bancorp Inc
NYSE:BHLB
|
0.032x |
|
Hannstar Display Corp
TW:6116
|
0.012x |
|
Adriatic Metals Plc
F:3FN
|
-0.035x |
|
Kestra Medical Technologies, Ltd. Common Stock
NASDAQ:KMTS
|
-0.064x |
|
Shandong Weigao Orthopaedic Device Co. Ltd. A
SHG:688161
|
N/A |
|
Taiji Computer Corp Ltd
SHE:002368
|
0.046x |
Annual Cash Flow Conversion Efficiency for Seaport Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025. View SPTX stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-92.55 Million | $-77.94 Million | 0.842x | -29.37% |
| 2024-12-31 | $-24.85 Million | $-29.63 Million | 1.192x | -- |
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-30… Read more